Ming Pei Yu

US Patent:

8491868, Jul 23, 2013

Filed:

Dec 21, 2007

Appl. No.:

12/448575

Inventors:

Ajay Purohit - Sudbury MA, US
Thomas D. Harris - Salem NH, US
Heike S. Radeke - South Grafton MA, US
Simon P. Robinson - Stow MA, US
Ming Yu - Chelmsford MA, US
David S. Casebier - Carlisle MA, US
Michael T. Azure - Renlop NH, US

Assignee:

Lantheus Medical Imaging, Inc. - North Billerica MA

International Classification:

A61K 51/00
A61K 51/04
C07C 279/06
A01N 47/44

US Classification:

424 189, 514565, 514634, 564230

Abstract:

Novel compounds that find use as imaging agents within nuclear medicine applications (PET imaging) for imaging of cardiac innervation are disclosed. These PET based radiotracers may exhibit increased stability, decreased NE release (thereby reducing side effects), improved quantitative data, and/or high affinity for VMAT over prior radiotracers. Methods of using the compounds to image cardiac innervation are also provided. In some instances the compounds are developed by derivatizing certain compounds with F in a variety of positions: aryl, alkyl, a keto, benzylic, beta-alkylethers, gamma-propylalkylethers and beta-proplylalkylethers. Alternatively or additionally, a methyl group a is added to the amine, and/or the catechol functionality is either eliminated or masked as a way of making these compounds more stable.

US Patent:

20110142815, Jun 16, 2011

Filed:

Jan 4, 2010

Appl. No.:

12/667687

Inventors:

Ming YU - Los Angeles CA, US

International Classification:

A61K 31/41
A61K 38/43
A61K 31/7052
C12N 5/09
A61P 35/00

US Classification:

424 941, 514381, 514 44 A, 435375

Abstract:

This invention describes methods and pharmaceutical compositions for combinational cancer treatments that are capable of inducing JNK phosphorylation and induce programmed cell death. It also identified genes as target for anti-cancer drug development and enhancement of the chemotherapeutic drug effect for the treatment of cancer. This invention points to a novel method and principle for a new avenue of developing more efficient and low or non cytotoxic cancer treatment.

US Patent:

20230052348, Feb 16, 2023

Filed:

Oct 14, 2021

Appl. No.:

17/501075

Inventors:

- Thousand Oaks CA, US
David Karl BEDKE - North Attleboro MA, US
Michael R. DEGRAFFENREID - San Francisco CA, US
Jiasheng FU - Foster City CA, US
Felix GONZALEZ LOPEZ DE TURISO - Cambridge MA, US
Ana GONZALEZ BUENROSTRO - San Mateo CA, US
Michael W. GRIBBLE JR. - Somerville MA, US
Michael G. JOHNSON - San Francisco CA, US
Todd J. KOHN - Thousand Oaks CA, US
Kexue LI - Newbury Park CA, US
Yunxiao LI - Thousand Oaks CA, US
Mike Elias LIZARZABURU - Pacifica CA, US
Yosup REW - Foster City CA, US
Joshua TAYGERLY - San Francisco CA, US
Yingcai WANG - Millbrae CA, US
Xuelei YAN - Foster City CA, US
Ming YU - Foster City CA, US
Jiang ZHU - Palo Alto CA, US
Manuel ZANCANELLA - San Mateo CA, US
Xian Yun JIAO - Belmont CA, US
Liusheng ZHU - Foster City CA, US
Xianghong WANG - Dublin CA, US
Julio C. MEDINA - San Carlos CA, US
Jason A. DUQUETTE - Millbrae CA, US
Jonathan B. HOUZE - Cambridge MA, US
Marc VIMOLRATANA - New York NY, US
Mario G. CARDOZO - San Francisco CA, US
Alan C. CHENG - San Francisco CA, US

Assignee:

AMGEN INC. - Thousand Oaks CA

International Classification:

C07D 513/10
C07D 513/20
C07D 515/10

Abstract:

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I,and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

US Patent:

20180133347, May 17, 2018

Filed:

May 12, 2016

Appl. No.:

15/153502

Inventors:

- North Billerica MA, US
David S. Casebier - Carlisle MA, US
Ming Yu - Chelmsford MA, US
Mikhail Kagan - North Chelmsford MA, US
Joel Lazewatsky - Auburndale MA, US

Assignee:

Lantheus Medical Imaging, Inc. - North Billerica MA

International Classification:

A61K 51/04

Abstract:

The present invention is directed, in part, to compounds and methods for imaging the central nervous system or cancer, comprising administering to a subject a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the subject using diagnostic imaging.

US Patent:

20170081662, Mar 23, 2017

Filed:

Sep 26, 2016

Appl. No.:

15/275863

Inventors:

Ming Yu - Los Angeles CA, US

International Classification:

C12N 15/113

Abstract:

This invention points to biological molecules and/or sequences that can be used as target for designing drug for treating cancer. This invention also points to biological sequences that can be used to target those molecules as a mean to treat cancer.

US Patent:

20140163088, Jun 12, 2014

Filed:

Jan 9, 2014

Appl. No.:

14/151539

Inventors:

Ming YU - Los Angeles CA, US

International Classification:

A61K 31/713
A61K 45/06
A61K 31/47
C07D 257/04
A61K 31/41

US Classification:

514 44 A, 548252, 514381

Abstract:

This invention describes methods and pharmaceutical compositions for combinational cancer treatments that are capable of inducing JNK phosphorylation and induce programmed cell death. It also identified genes as target for anti-cancer drug development and enhancement of the chemotherapeutic drug effect for the treatment of cancer. This invention points to a novel method and principle for a new avenue of developing more efficient and low or non cytotoxic cancer treatment.